GPT and Thrombocytopenia: In the colistin sulfate group, the side effects were predominantly AST elevation, with 9 (28.1%) patients suffering AST elevation during treatment, followed by nephrotoxicity (15.0%), ALT elevation (13.3%), thrombocytopenia in 4 patients (13.3%) and TBiL elevation in the least (6.1%).